Speaker illustration

Doctor Andrew Whittaker

AstraZeneca, Gothenburg (Sweden)

Andrew is a consultant cardiologist by training who currently works in translational research and early clinical drug development at AstraZeneca. He qualified from University of Leicester Medical School in 2000 and completed his general medical training before undertaking a 3-year period of research under the supervision of Sir Professor Nilesh Samani for which he was awarded his MD[Res] for his work on the role of endothelial progenitor cells and telomeres in coronary artery disease. Andrew completed his higher medical & cardiology training, then completed two sub-specialty fellowships in advanced percutaneous coronary intervention, and was appointed consultant cardiologist in January 2015. In his industry role, Andrew has been developing novel drug repurposing hypotheses utilising a selection of AstraZeneca’s discontinued compounds across all therapy areas. In addition, Andrew works as a Study Physician in the CV, renal & metabolic disease unit on early drug development projects

Clinical pharmacology of AZD9977, a novel, selective mineralocorticoid receptor (MR) modulator without K+-sparing properties

Event: ESC Congress 2019

Topic: Aldosterone Antagonists

Session: Cardiovascular pharmacotherapy


ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb